Osimertinib-induced hearing loss: an uncommon aftereffect of a novel drug—a case report
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have significantly improved survival outcomes of advanced non-small cell lung cancer (NSCLC). Nonetheless, usage of TKIs is not without adverse effects, as it has been reported to cause irreversible sensorineural h...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Published: |
Springer Medizin
2022
|
| Subjects: | |
| Online Access: | http://eprints.um.edu.my/43745/ https://doi.org/10.1186/s43163-022-00250-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|